There is nothing romantic about Alzheimer’s disease, a condition as different as could be from the spes phthisica, the heightened creativity and sensitivity said to be caused by tuberculosis. The only similarities are that in the days when the spes was being celebrated by La Traviata and La Bohème, tuberculosis was as common – and incurable – as Alzheimer’s is today. It was no surprise, then, that massive media interest was generated earlier this year when the pharmaceutical company Eli Lilly announced that its monoclonal antibody donanemab slowed cognitive decline by 35 per cent in some Alzheimer’s sufferers.